The medical field has made some significant advances in unlocking the key to disease. One of the men leading the way in this territory is a man named Dr. Scott Rocklage. He received his P.HD in Chemistry from the University of Massachusetts. He is also the managing partner at a company called 5 AM Ventures.
Scott Rocklage is a veteran when it comes to researching life science and the applications it can be used for. Scott Rocklage has had over three decades of experience in the medical field and leads the way when it came to FDA (Food and Drug Administration)approval for three new applications. They are Omniscan, Teslascan, and Cubicin. Now Dr. Scott Rocklage is helping lead the way on a new front. That front is fighting genetic disorders.
Dr. Scoot Rocklage with his team at 5 Am Ventures and other companies have come together on a mission. That mission is to unlock the key to curing many genetic disorders that run in families. The research takes place at the office of Dr. Matthew Disney and is the main researcher on this team. The goal of the current research is to figure out what causes a disease known as DM1. DM1 occurs when RNA cells in the body reach toxic levels. When this occurs, muscles of the body become defective. This can include the hormonal system, the gastrointestinal system and most importantly the heart.This type of disease can be passed down in families and become hereditary.
Work on solving the problem of DM1 has been going on for more than a decade. With the help of companies like 5 AM Ventures and Expansion Therapeutics, Dr. Scott Rocklage and Dr. Matthew Disney along with others are working on new treatments in order to stop the spread of DM1 in people and families. The two companies are also working on other projects together as well.
Dr. Scott Rocklage is only one piece of the puzzle when it comes to solving the mystery of DM1 and genetic disorders. He is very happy to lend a helping hand to such a worthy cause. Learn more: https://www.dialdish.com/scott-rocklage-seeks-to-conquer-cancer-by-targeting-mutant-rna-molecules/